Aminoalkylindole
Aminoalkylindoles (AAIs) are a family of cannabinergic compound that act as a cannabinoid receptor agonist. They were invented by pharmaceutical company Sterling-Winthrop in the early 1990s as potential nonsteroidal anti-inflammatory agents.[1]
Legality
Aminoalkylindole are now commonly found in synthetic cannabis designer drugs.[2]
In the United States, the DEA added the aminoalkylindole JWH-200 to Schedule I of the Controlled Substances Act on 1 March 2011 for 12 months.[2][3]
gollark: https://osmarks.tk/nemc/
gollark: In this country the government has "computing" lessons which involve just teaching people Scratch, which annoyed me enough that I wrote a blog post criticizing this.
gollark: It would also be nice if people actually knew anything about networking.
gollark: I fear that some sort of computer troubleshooting class may just end up teaching people to blindly try one specific thing they learned instead of... actually problem-solving. Which would admittedly be better than now.
gollark: People just see an error of some sort, and immediately their brain shuts down, even if it specifies what to do about it.
References
- Emmanuel S. Onaivi (2006). Marijuana and Cannabinoid Research: Methods and Protocols. Springer. pp. 128–. ISBN 978-1-59259-999-8.
- "Synthetic Cannabinoids". American Association for Clinical Chemistry. 2013-02-01. Retrieved 2013-11-17.
- "Schedules of Controlled Substances: Temporary Placement of Five Synthetic Cannabinoids Into Schedule I". Federal Register. 2011-03-01. Retrieved 2013-11-17.
External links
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.